180 related articles for article (PubMed ID: 8076367)
1. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic and biologic properties of droloxifene, a new antiestrogen.
Eppenberger U; Wosikowski K; Küng W
Am J Clin Oncol; 1991; 14 Suppl 2():S5-14. PubMed ID: 1962598
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
4. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB
Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818
[TBL] [Abstract][Full Text] [Related]
5. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
Rauschning W; Pritchard KI
Breast Cancer Res Treat; 1994; 31(1):83-94. PubMed ID: 7981460
[TBL] [Abstract][Full Text] [Related]
6. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.
Helle SI; Anker GB; Tally M; Hall K; Lønning PE
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):167-71. PubMed ID: 8645625
[TBL] [Abstract][Full Text] [Related]
7. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
8. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
9. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
10. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells.
Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K
Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842
[TBL] [Abstract][Full Text] [Related]
11. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
[TBL] [Abstract][Full Text] [Related]
12. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
13. No loss of estrogenic or anti-estrogenic activity after demethylation of droloxifene (3-OH-tamoxifen).
Löser R; Seibel K; Eppenberger U
Int J Cancer; 1985 Dec; 36(6):701-3. PubMed ID: 4066073
[TBL] [Abstract][Full Text] [Related]
14. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
16. Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
Haarstad H; Gundersen S; Wist E; Raabe N; Mella O; Kvinnsland S
Acta Oncol; 1992; 31(4):425-8. PubMed ID: 1632978
[TBL] [Abstract][Full Text] [Related]
17. Investigations of droloxifene and other hormonal manipulations on N-nitrosomethylurea-induced rat mammary tumours. 2. Influence on oestrogen receptor.
Görlich M; Winterfeld G; Hauff P; Arnold W; Fichtner I; Staab HJ
J Cancer Res Clin Oncol; 1992; 119(2):97-100. PubMed ID: 1429832
[TBL] [Abstract][Full Text] [Related]
18. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced genes in the uterus of ovariectomized rats and their regulation by droloxifene and tamoxifen.
Rivera-Gonzalez R; Petersen DN; Tkalcevic G; Thompson DD; Brown TA
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):13-24. PubMed ID: 9569006
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factors in breast cancer.
Helle SI; Lønning PE
Acta Oncol; 1996; 35 Suppl 5():19-22. PubMed ID: 9142960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
